Home › Research › Biomarkers
Validation of blood biomarkers for Alzheimer Disease in Thai Cohort
Vorapun Senanarong, Tanyaluck Thientunyakit, Chatchawan Rattanabannakit, Natthamon Wongkom, Pathitta Dujada, Atthapon Raksthaput, Sunisa Chaichanettee, Paphawadee Phoyoo et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background Our objective of this study is to identify suitable local cut‐off values of plasma‐based biomarkers in Alzheimer disease (AD) in the discrimination of AD and non‐AD subgroups in Thai population. Method We conducted a prospective study in 51 individuals with clinically diagnosed AD (15 had amyloid PET positive (≥ 30 centiloid, CL), 16 had CSF Aβ 42 ≤547 pg/mL and CSF pTau 181 >57 pg/mL regarded as amyloid positive AD), 34 individuals with clinically diagnosed non‐AD dementia (9 had amyloid PET negative, 25 had CSF Aβ 42 and CSF pTau181 negative), and 12 individuals with mild cognitive impairment (MCI) or normal controls (6 had amyloid PET negative and 6 had CSF Aβ 42 and CSF pTau181 negative). Aβ‐PET using 18F‐florbetapir and plasma biomarkers (Aβ 40 , Aβ 42 , p ‐tau181, pTau 217, Glial fibrillary acidic protein (GFAP)) were obtained in all subjects within 6 months before or after the PET study. The quantitative analysis of Aβ‐PET to obtain Centiloid (CL) followed the standard method using the SPM8 pipeline. Blood biomarker analysis utilized Simoa® Quanterix immunoassay. CSF Aβ42, t‐Tau and p ‐Tau were measured separately, in duplicate, by commercially available sandwich ELISA kits (Innotest; Innogenetics/Fujirebio, Ghent, Belgium). Participants underwent a standardized diagnostic dementia evaluation. Result Among 97 individuals, 54 (55.7%) amyloid positive and 43(44.3%) amyloid negative individuals were included in this blood biomarkers validation study. Mean age was 65.86(8.01) years, mean TMSE was 19.57(7.44) and mean MOCA was 15.48(7.27). Mean(SD) plasma Aβ 42/40, pTau181, pTau 217, NFL, and GFAP were 0.054(0.013) pg/mL, 37.591(18.975) pg/mL, 1.088(0.949) pg/mL, 102.703(412.308) pg/mL, and 162.459(107.223) pg/mL respectively. Utilizing single cut off from ROC analysis: the cut off points are as followed; for plasma Aβ42/40≤0.054pg/mL (AUC(SE)=0.716(0.064), p 32.7pg/mL (AUC(SE)=0.812(0.058), p 0.522pg/mL (AUC(SE)=0.856(0.056), p 119pg/mL (AUC(SE)=0.796(0.058), p <0.0001, accuracy77.89(68.22‐85.77)). For high and low cut‐ points, the results were shown in table 1. Conclusion Plasma biomarkers showed promising diagnostic performances and potential clinical usefulness in diagnosing dementia. Plasma p ‐tau217 was best differentiates AD positive from AD negative groups, followed by plasma GFAP, pTau181, and Aβ42/40 ratio. Thank you Health Systems Research Institute (Thailand) grant support for this study
What this study adds
Evidence grade: Low
The record lists 51 participants. This study aimed to establish local cut-off values for plasma biomarkers to distinguish Alzheimer from non-Alzheimer groups in a Thai population. Reported effect size: 55.7%; 44.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Senanarong, V., Thientunyakit, T., Rattanabannakit, C., Wongkom, N., Dujada, P., Raksthaput, A., et al. (2025). Validation of blood biomarkers for Alzheimer Disease in Thai Cohort. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_102473
Vancouver
Senanarong V, Thientunyakit T, Rattanabannakit C, Wongkom N, Dujada P, Raksthaput A, et al. Validation of blood biomarkers for Alzheimer Disease in Thai Cohort. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_102473. PMID: 41452241.
BibTeX
@article{senanarong2025-41452241,
author = {Senanarong, Vorapun and Thientunyakit, Tanyaluck and Rattanabannakit, Chatchawan and Wongkom, Natthamon and Dujada, Pathitta and Raksthaput, Atthapon and Chaichanettee, Sunisa and Phoyoo, Paphawadee and others},
title = {{Validation of blood biomarkers for Alzheimer Disease in Thai Cohort}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_102473},
pmid = {41452241},
url = {https://doi.org/10.1002/alz70856_102473}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Result Among 97 individuals, 54 (55.7%) amyloid positive and 43(44.3%) amyloid negative individuals were included in this blood biomarkers validation study.
- For high and low cut‐ points, the results were shown in table 1.
Why it matters
This study aimed to establish local cut-off values for plasma biomarkers to distinguish Alzheimer from non-Alzheimer groups in a Thai population. It is a validation study of diagnostic thresholds and reports no treatment or prevention outcome.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants51
- Effect size55.7%; 44.3%
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 51 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Philip Scheltens: h-index 181 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Amsterdam UMC Location Vrije Universiteit Amsterdam: institution h-index 938 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41452241) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_102473
- PubMed: 41452241
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.